For example, out of three cohorts of NSCLC patients with increasing MET/CEP7 ratios (1.8-2.2, 2.2–5.0 and above 5.0), the last had the highest tumor response rates to MET inhibitor crizotinib [14]. This evidence concerns the gene MET and neoplasm.